2024-03-05 22:20:25 ET
Rigel Pharmaceuticals, Inc. (RIGL)
Q4 2023 Earnings Conference Call
March 5, 2024 4:30 AM ET
Company Participants
Ray Furey - Executive Vice President, General Counsel and Corporate Secretary
Raul Rodriguez - President and Chief Executive Officer
Dave Santos - Chief Commercial Officer
Francois Di Trapani - Senior Vice President of Medical Affairs
Dean Schorno - Chief Financial Officer
Conference Call Participants
Yigal Nochomovitz - Citigroup
Kristen Kluska - Cantor Fitzgerald
Kalpit Patel - B. Riley Securities
Presentation
Operator
Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2023. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce you to our first speaker, Ray Furey, Rigel’s Executive Vice President, General Counsel and Corporate Secretary. Thank you Mr. Furey. You may begin.
Ray Furey
Welcome to our fourth quarter and year end 2023 financial results and business update conference call. Financial press release for the fourth quarter and year end 2023 was issued a short while ago and can be viewed along with the slides for this presentation in the News & Events section of our Investor Relations site on rigel.com.
As a reminder, during today’s call we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found on our most recent annual report on Form 10-K for the year ended December 31st, 2023, on file with the SEC.
Any forward-looking statements are made only as of today’s date and we undertake no obligation to update those forward-looking statements to reflect subsequent events or circumstances.
At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul?...
Read the full article on Seeking Alpha
For further details see:
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript